UGT2B28

Across TCGA pan-cancer cohorts, UGT2B28 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated UGT2B28 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher UGT2B28 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UGT2B28 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and COAD are the cancer types where UGT2B28 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.074	0.703	<.001	48	view →
UCEC	DFS	Median	All	1.000	0.829	.017	30	view →
COAD	OS	Median	II,III,IV	0.212	0.792	.007	16	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.388	0.727	.002	6	view →
READ	OS	Median	III,IV	0.328	0.751	.003	3	view →
HNSC	OS	Median	All	0.313	0.662	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

UGT2B28–ESCA (OS)

Open the ESCA breakdown →